These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10894297)

  • 41. Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.
    Abel K; Rourke T; Lu D; Bost K; McChesney MB; Miller CJ
    J Infect Dis; 2004 Nov; 190(9):1697-705. PubMed ID: 15478078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abrogation of AIDS vaccine-induced cytotoxic T-lymphocyte efficacy in vivo due to a change in viral epitope flanking sequences.
    Moriya C; Igarashi H; Takeda A; Tsukamoto T; Kawada M; Yamamoto H; Inoue M; Iida A; Shu T; Hasegawa M; Nagai Y; Matano T
    Microbes Infect; 2008 Mar; 10(3):285-92. PubMed ID: 18316225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
    Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
    J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys.
    McKay PF; Schmitz JE; Barouch DH; Kuroda MJ; Lifton MA; Nickerson CE; Gorgone DA; Letvin NL
    J Immunol; 2002 Jan; 168(1):332-7. PubMed ID: 11751978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.
    Barouch DH; Craiu A; Santra S; Egan MA; Schmitz JE; Kuroda MJ; Fu TM; Nam JH; Wyatt LS; Lifton MA; Krivulka GR; Nickerson CE; Lord CI; Moss B; Lewis MG; Hirsch VM; Shiver JW; Letvin NL
    J Virol; 2001 Mar; 75(5):2462-7. PubMed ID: 11160750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
    De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ
    J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
    Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viral reservoir is suppressed but not eliminated by CD8 vaccine specific lymphocytes.
    Yin J; Dai A; Shen A; Lecureux J; Lewis MG; Boyer JD
    Vaccine; 2010 Feb; 28(8):1924-31. PubMed ID: 20188248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.
    Seth A; Ourmanov I; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Wyatt L; Carroll M; Moss B; Venzon D; Letvin NL; Hirsch VM
    J Virol; 2000 Mar; 74(6):2502-9. PubMed ID: 10684264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Schmitz JE; Kuroda MJ; Santra S; Sasseville VG; Simon MA; Lifton MA; Racz P; Tenner-Racz K; Dalesandro M; Scallon BJ; Ghrayeb J; Forman MA; Montefiori DC; Rieber EP; Letvin NL; Reimann KA
    Science; 1999 Feb; 283(5403):857-60. PubMed ID: 9933172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses.
    Robinson TM; Sidhu MK; Pavlakis GN; Felber BK; Silvera P; Lewis MG; Eldridge J; Weiner DB; Boyer JD
    J Med Primatol; 2007 Aug; 36(4-5):276-84. PubMed ID: 17669216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.
    Rose NF; Marx PA; Luckay A; Nixon DF; Moretto WJ; Donahoe SM; Montefiori D; Roberts A; Buonocore L; Rose JK
    Cell; 2001 Sep; 106(5):539-49. PubMed ID: 11551502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AIDS research. Merck reemerges with a bold AIDS vaccine effort.
    Cohen J
    Science; 2001 Apr; 292(5514):24-5. PubMed ID: 11294193
    [No Abstract]   [Full Text] [Related]  

  • 55. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization.
    Kawahara M
    Clin Immunol; 2008 Dec; 129(3):492-8. PubMed ID: 18849196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.
    Hu X; Valentin A; Dayton F; Kulkarni V; Alicea C; Rosati M; Chowdhury B; Gautam R; Broderick KE; Sardesai NY; Martin MA; Mullins JI; Pavlakis GN; Felber BK
    J Immunol; 2016 Nov; 197(10):3999-4013. PubMed ID: 27733554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.
    Schell JB; Bahl K; Folta-Stogniew E; Rose N; Buonocore L; Marx PA; Gambhira R; Rose JK
    Virology; 2015 Feb; 476():405-412. PubMed ID: 25591175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus.
    Kato M; Igarashi H; Takeda A; Sasaki Y; Nakamura H; Kano M; Sata T; Iida A; Hasegawa M; Horie S; Higashihara E; Nagai Y; Matano T
    Vaccine; 2005 May; 23(24):3166-73. PubMed ID: 15837216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
    Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL
    J Virol; 2003 Nov; 77(21):11563-77. PubMed ID: 14557642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.